Pictet Asset Management Holding SA trimmed its stake in 10x Genomics (NASDAQ:TXG – Free Report) by 49.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,030 shares of the company’s stock after selling 103,226 shares during the period. Pictet Asset Management Holding SA owned about 0.08% of 10x Genomics worth $9,372,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Quantinno Capital Management LP raised its position in shares of 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after buying an additional 744,558 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of 10x Genomics by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock valued at $43,357,000 after buying an additional 525,369 shares during the period. Hsbc Holdings PLC acquired a new stake in 10x Genomics during the first quarter worth about $5,945,000. Quantedge Capital Pte Ltd grew its position in 10x Genomics by 104.2% during the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after buying an additional 212,600 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new stake in 10x Genomics during the third quarter worth about $11,364,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.
10x Genomics Stock Performance
Shares of TXG stock opened at $58.19 on Monday. 10x Genomics has a 52-week low of $15.12 and a 52-week high of $102.81. The stock has a market cap of $7.58 billion, a price-to-earnings ratio of -111.90 and a beta of 2.03. The firm has a fifty day moving average of $73.92 and a 200-day moving average of $42.57.
10x Genomics (NASDAQ:TXG – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The company had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. During the same period last year, the firm earned ($0.22) EPS. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, sell-side analysts predict that 10x Genomics will post -0.74 earnings per share for the current year.
Wall Street Analysts Forecast Growth
TXG has been the topic of several research reports. TD Cowen boosted their price target on 10x Genomics from $47.00 to $70.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Citigroup raised their price objective on 10x Genomics from $50.00 to $60.00 and gave the stock a “hold” rating in a research report on Friday, November 6th. JPMorgan Chase & Co. reduced their price objective on 10x Genomics from $70.00 to $65.00 and set a “neutral” rating for the company in a research report on Monday, November 9th. Barclays decreased their price objective on 10x Genomics from $110.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, November 9th. Finally, Leerink Partners boosted their price objective on 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research report on Tuesday, September 29th. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and an average price target of $68.40.
Check Out Our Latest Stock Analysis on TXG
Insider Transactions at 10x Genomics
In other 10x Genomics news, Director Shehnaaz Suliman sold 5,723 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the transaction, the director owned 23,792 shares in the company, valued at $1,931,672.48. This trade represents a 19.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Taich sold 46,388 shares of 10x Genomics stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total value of $2,995,273.16. Following the sale, the chief financial officer directly owned 316,344 shares in the company, valued at $20,426,332.08. The trade was a 12.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 190,333 shares of company stock valued at $12,604,970. Corporate insiders own 8.84% of the company’s stock.
About 10x Genomics
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Read More
- Five stocks we like better than 10x Genomics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
